An initiative of IBA Proton Therapy
Campus your proton
therapy community
  • Resource center
  • Training
  • Events
  • About
  • Log in
  • Resource center
  • Training
  • Events
  • About
  • Log in
An initiative of IBA Proton Therapy

Your results for

Filter by

Filter by
Results

Filter by

Content type
  • Event - Do not use (0)
  • Podcast (0)
  • Publications (127)
  • Training (0)
  • User case (2)
  • User meeting (0)
  • Webinar (9)
  • White paper (1)
Key content topics
Key audience
  • Newcomers (0)
Top cancer treatments
  • Brain and CNS (88)
  • Breast (59)
  • Gastro-intestinal (125)
  • Genito-urinary (51)
  • (-) Gynecological (7)
  • (-) Head and neck (133)
  • Hodgkin and Non-Hodgkin lymphoma (16)
  • Ocular (12)
  • Pediatric (100)
  • Reirradiation (12)
  • Sarcomas (18)
  • Thoracic (91)
  • Reset filters
  • (-) Gynecological
  • (-) Head and neck

Gross tumor volume margin and local control in p16-positive oropharynx cancer patients treated with intensity modulated proton therapy.

29/02/2024
/ Publications

This is a retrospective analysis of patients with p16+ OPC treated with IMPT. Sixty patients were included for analysis with a median follow-up of 17 months...

Osteoradionecrosis of the Jaw Following Proton Radiation Therapy for Patients With Head and Neck Cancer.

29/02/2024
/ Publications

Published in JAMA, this study reported the prevalence and clinical characteristics of ORN in patients with oral and oropharyngeal cancer (OOPC) treated with PRT...

Acute radiation dermatitis among patients with nasopharyngeal carcinoma treated with proton beam therapy: Prognostic factors and treatment outcomes.

29/02/2024
/ Publications

This study reported incidence of acute radiation dermatitis (ARD) of 57 NPC patients treated with PBT. The maximum ARD grade was 1, 2, and 3 in 26 (45.6%), 24...

Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma.

01/03/2024
/ Publications

This study analyzed 242 patients treated with PT-ReRT. Median follow-up was 12.0 months for all patients and 24.5 months for living patients. Median PT-ReRT...

Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group.

01/03/2024
/ Publications

This report presented the results of patients with non-CNS malignancies treated in the UK proton overseas program. Four hundred and ninety-five patients were...

Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma.

08/04/2024
/ Publications
/
IMRT
IMPT

To compare the oncologic outcomes between proton therapy and intensity-modulated radiation therapy (IMRT) for head and neck squamous cell carcinoma (HNSCC)...

Longitudinal Assessment of Quality of Life in Nasopharyngeal Cancer Patients Treated with Intensity-Modulated Proton Therapy and Volumetric Modulated Arc Therapy at Different Time Points.

06/05/2024
/ Publications
/
IMPT
Quality of life
VMAT

This is a longitudinal assessment of QoL on 287 NPC patients treated with IMPT (n=41) and VMAT (n=246). Both groups exhibited improved scores of global QoL...

Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer.

06/05/2024
/ Publications
/
FLASH Therapy
Reirradiation
Toxicity
Survival

Published by the Upenn group, this study reported reduced xerostomia with FLASH proton compared to standard proton therapy in mice. The head and neck area of...

Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy

14/04/2021
/ Publications
/
Survival

This study reported clinical outcomes of 68 patients with major salivary gland tumors including the parotid gland (75.0%) and adenoid cystic carcinoma (22.1%)...

Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.

14/06/2021
/ Publications
/
Toxicity
Survival
IMPT

Seventy-seven patients with nonmetastatic NPC received IMPT (n=28) or IMRT(n=49). With a median follow-up time of 30.3 months, IMPT was associated with lower...

Pagination

  • Previous page ‹
    • Page 11
    • Current page 12
    • Page 13
  • Next page ›
Campus
Subscribe to our newsletter
Follow us on
  • Facebook
  • Linkedin
  • Twitter
  • Youtube
Contact us
  • About Campus
  • Resources
  • Training
  • Connect
  • IBA Worldwide
  • Back to IBA Proton Therapy
Life Science
  • Legal
  • Terms of Use
  • Privacy policy
  • Cookies policy
  • Manage cookies
  • Code of conduct

Cookies policy

If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.

Manage your cookie preferences

Respect for your privacy is still a priority for us at IBA.

Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.

Accept all cookies
Adapt my preferences
Cookies policies